Sun-Novo(SH:688621) Xin Lang Cai Jing·2025-10-14 07:13Core Viewpoint - Sunshine Nuohua's stock price has declined for five consecutive days, with a total drop of 11.3% during this period, indicating potential concerns among investors regarding the company's performance and market conditions [1]. Company Overview - Sunshine Nuohua Pharmaceutical Research Co., Ltd. is located in Changping District, Beijing, and was established on March 9, 2009. The company went public on June 21, 2021. Its main business involves the development of generic drugs, consistency evaluation, and innovative drug development, primarily focusing on pharmaceutical research, clinical trials, and bioanalysis [1]. - The revenue composition of the company is heavily weighted towards CRO (Contract Research Organization) services, accounting for 99.91% of total revenue, with other services contributing only 0.09% [1]. Shareholder Insights - Anxin Fund's Anxin Medical Health Stock A (010709) is among the top ten circulating shareholders of Sunshine Nuohua. In the second quarter, it reduced its holdings by 266,500 shares, retaining 1.442 million shares, which represents 1.29% of the circulating shares. The estimated floating loss today is approximately 1.5285 million yuan, with a total floating loss of 10.8872 million yuan over the five-day decline [2]. - Anxin Medical Health Stock A was established on January 12, 2021, with a current scale of 442 million yuan. Year-to-date returns stand at 63.14%, ranking 222 out of 4220 in its category, while the one-year return is 53.22%, ranking 797 out of 3857 [2]. Fund Positioning - Anxin Medical Health Stock A has Sunshine Nuohua as its fourth-largest holding, with 1.442 million shares representing 7.61% of the fund's net value. The estimated floating loss for today is around 1.5285 million yuan, with a cumulative floating loss of 10.8872 million yuan during the recent five-day decline [3].